Celon Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Celon Pharma is a dividend paying company with a current yield of 0.3%.
Key information
0.3%
Dividend yield
-2.8%
Buyback Yield
| Total Shareholder Yield | -2.5% |
| Future Dividend Yield | 0.3% |
| Dividend Growth | 2.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | zł0.080 |
| Payout ratio | 23% |
Recent dividend and buyback updates
Recent updates
Statutory Earnings May Not Be The Best Way To Understand Celon Pharma's (WSE:CLN) True Position
Nov 28
A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price
Aug 21Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: CLN is not paying a notable dividend for the Polish market, therefore no need to check if payments are stable.
Growing Dividend: CLN is not paying a notable dividend for the Polish market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Celon Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CLN) | 0.3% |
| Market Bottom 25% (PL) | 3.0% |
| Market Top 25% (PL) | 8.4% |
| Industry Average (Pharmaceuticals) | 2.6% |
| Analyst forecast (CLN) (up to 3 years) | 0.3% |
Notable Dividend: CLN's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (2.97%).
High Dividend: CLN's dividend (0.3%) is low compared to the top 25% of dividend payers in the Polish market (8.43%).
Earnings Payout to Shareholders
Earnings Coverage: CLN is not paying a notable dividend for the Polish market.
Cash Payout to Shareholders
Cash Flow Coverage: CLN is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:34 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Vladimira Urbankova | Erste Group Bank AG |